Fund · iShares U.S. Medical Devices ETF · measured from SEC filings
IHI holdings
IHI reports 49 holdings and behaves like 11.9 equally weighted ones, computed from its SEC Form N-PORT filing for 2026-06-30. The fact sheet publishes the first number; this page computes the second, and traces it across 28 quarters of filings.
Measured concentration
as of 2026-06-30Read this figure with the following in mind
2.1% of net assets is securities-lending cash collateral, excluded from the figure; counted as filed the fund would read 11.9
The figure below is what the filing says, published unchanged. What it may not do is sit beside a plain long-only fund and be read as the same quantity. How comparability is decided.
Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 100% at a quoted market price (level 1), 4 issuer countries.
What stands out
as of 2026-06-30IHI's largest investment is Abbott Laboratories at 16.93% of net assets. Intuitive Surgical Inc and Stryker Corp follow; the three together are 43.66%. Ten companies are 74.66% of the fund; the other 39 share the rest. Among the 721 equity funds measured here, IHI behaves like 11.9 holdings against a median of 42.4 — 3.6 times more concentrated than the median. Across 28 quarterly filings IHI has held roughly steady since 2019-09-30 (14.5 then, 11.9 now). Between the 2026-03-31 and 2026-06-30 filings 3 positions were added and 4 dropped; 5.2% of the weight moved.
Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.
Every filing since 2019
28Between 2019-09-30 and 2026-06-30, IHI went from behaving like 14.5 equally weighted positions to 11.9 — 18% fewer, while its top ten went from 71.96% to 74.66% of net assets. Read across the funds on the concentration-over-time table.
| Period | Holdings | Effective | Top 10 | Largest |
|---|---|---|---|---|
| 2026-06-30 | 49 | 11.9 | 74.66% | 16.94% |
| 2026-03-31 | 50 | 12 | 74.55% | 16.98% |
| 2025-12-31 | 49 | 11.5 | 75.73% | 17.55% |
| 2025-09-30 | 52 | 11.4 | 76.06% | 19.31% |
| 2025-06-30 | 49 | 11.1 | 76.11% | 18.83% |
| 2025-03-31 | 50 | 11.4 | 75.52% | 18.9% |
| 2024-12-31 | 49 | 12 | 74.28% | 16.76% |
| 2024-09-30 | 50 | 12.7 | 73.46% | 16.64% |
Earlier filings (20 more, back to 2019-09-30)
| Period | Holdings | Effective | Top 10 | Largest |
|---|---|---|---|---|
| 2024-06-30 | 52 | 13.2 | 72.08% | 16.06% |
| 2024-03-31 | 55 | 13.7 | 71.32% | 16.72% |
| 2023-12-31 | 57 | 13.6 | 70.44% | 17.67% |
| 2023-09-30 | 55 | 13.6 | 71.29% | 17.35% |
| 2023-06-30 | 64 | 14.3 | 70.93% | 14.69% |
| 2023-03-31 | 68 | 13.5 | 70.7% | 17.35% |
| 2022-12-31 | 65 | 12.7 | 71.75% | 17.41% |
| 2022-09-30 | 66 | 12.8 | 70.79% | 17.58% |
| 2022-06-30 | 67 | 12.1 | 71.98% | 17.71% |
| 2022-03-31 | 69 | 13.3 | 71.42% | 16.1% |
| 2021-12-31 | 68 | 12.7 | 72.4% | 16.8% |
| 2021-09-30 | 67 | 14.8 | 70.66% | 13.21% |
| 2021-06-30 | 68 | 14.9 | 70.87% | 12.77% |
| 2021-03-31 | 69 | 14.8 | 69.66% | 14.26% |
| 2020-12-31 | 66 | 15.3 | 69.28% | 13.12% |
| 2020-09-30 | 66 | 14.4 | 70.67% | 14.2% |
| 2020-06-30 | 62 | 14.7 | 70.76% | 13.72% |
| 2020-03-31 | 59 | 14.9 | 70.29% | 13.87% |
| 2019-12-31 | 59 | 14.6 | 71.91% | 13.06% |
| 2019-09-30 | 59 | 14.5 | 71.96% | 13.39% |
One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.
As filed, collateral included
2.15% collateralIHI's filing lists 50 positions including 2.15% of net assets in securities-lending cash collateral. Counted as filed the fund reads 11.9 effective holdings with a top ten of 74.62%; on its own investments — the figure above — it reads 11.9 with a top ten of 74.66%. The collateral is matched by a liability and is not a holding the fund chose; since 2026-09-18 every figure on this site sets it aside (methodology). Both numbers are in the data.
Largest positions, as filed
as of 2026-06-30The 15 largest of 49 positions in IHI's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: IHI.csv.gz.
| # | Position | Weight | Cumulative |
|---|---|---|---|
| 1 | ABBOTT LABORATORIES | 16.94% | 16.9% |
| 2 | INTUITIVE SURGICAL, INC. | 15.10% | 32.0% |
| 3 | STRYKER CORPORATION | 11.64% | 43.7% |
| 4 | EDWARDS LIFESCIENCES CORPORATION | 4.76% | 48.4% |
| 5 | BECTON, DICKINSON AND COMPANY | 4.63% | 53.1% |
| 6 | GE HEALTHCARE TECHNOLOGIES INC. | 4.51% | 57.6% |
| 7 | MEDTRONIC PUBLIC LIMITED COMPANY | 4.41% | 62.0% |
| 8 | RESMED INC. | 4.38% | 66.4% |
| 9 | IDEXX LABORATORIES, INC. | 4.27% | 70.6% |
| 10 | DEXCOM, INC. | 4.03% | 74.7% |
| 11 | BOSTON SCIENTIFIC CORPORATION | 3.99% | 78.7% |
| 12 | STERIS PUBLIC LIMITED COMPANY | 3.20% | 81.9% |
| 13 | ZIMMER BIOMET HOLDINGS, INC. | 2.58% | 84.4% |
| 14 | PENUMBRA, INC. | 1.92% | 86.4% |
| 15 | BAXTER INTERNATIONAL INC. | 1.71% | 88.1% |
By country of issuer
as of 2026-06-30Share of IHI's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.
| Country | Share |
|---|---|
| United States | 91.45% |
| Ireland° | 7.61% |
| United Kingdom | 0.70% |
| Jersey° | 0.25% |
Returns the fund reported
2019-07 – 2026-06Monthly total returns from Item B.5 of IHI's own filings, 84 months on record. Not computed here and not from a price feed.
Cross-checked against a series computed separately from prices: median difference 0.04 percentage points over 84 months, which is roughly the distributions. Every month with the filing it came from: IHI.json · all funds.
Who borrows IHI's shares
2026-06-30The fund lends its holdings, and Item B.4.a of the filing names every firm holding them. At 2026-06-30, $62m was out to 16 borrowers, 2.04% of net assets. The largest, SG AMERICAS SECURITIES LLC, held 16.1% of it.
| Borrower | On loan | Share of the loan |
|---|---|---|
| SG AMERICAS SECURITIES LLC | $10m | 16.1% |
| CITIGROUP GLOBAL MARKETS INC. | $9m | 14.9% |
| BNP PARIBAS SECURITIES CORP | $7m | 11.4% |
| BofA Securities, Inc. | $6m | 10.2% |
| Jefferies LLC | $5m | 8.8% |
Cash collateral reported against the loan: 2.15% of net assets, 105.4% of the amount lent. That is a floor on the collateral, not the whole of it — collateral the fund does not hold as a position is not in this filing, so a figure under 100% is not evidence of under-collateralisation. How that figure behaves across all funds. Every quarter IHI has filed, with each borrower: IHI.json · all funds.
Since the previous filing
2026-03-31 → 2026-06-3050 positions became 49: 3 added (0.0% of the fund at the later date), 4 dropped (3.4% at the earlier date). Half the sum of all weight changes, a turnover proxy: 5.2%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of IHI compared this way, as a feed: changes.xml · all funds: filings received.
| Largest increases | 2026-03-31 | 2026-06-30 | Largest decreases | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|
| STRYKER CORPORATION | 10.77% | 11.64% | INTUITIVE SURGICAL, INC. | 15.57% | 15.10% |
| DEXCOM, INC. | 3.28% | 4.03% | INSULET CORPORATION | 2.00% | 1.63% |
| BAXTER INTERNATIONAL INC. | 1.17% | 1.71% | BOSTON SCIENTIFIC CORPORATION | 4.28% | 3.99% |
| GLAUKOS CORPORATION | 0.84% | 1.27% | MEDTRONIC PUBLIC LIMITED COMPANY | 4.62% | 4.41% |
| EDWARDS LIFESCIENCES CORPORATION | 4.47% | 4.76% | IDEXX LABORATORIES, INC. | 4.44% | 4.27% |
| STERIS PUBLIC LIMITED COMPANY | 2.94% | 3.20% | TRANSMEDICS GROUP, INC. | 0.46% | 0.36% |
New: XAV HEALTH CARE SEP26 (0.00%), XAK TECHNOLOGY SEP26 (0.00%), HOLOGIC INC CVR (0.00%). Gone: HOLOGIC, INC. (2.28%), MASIMO CORPORATION (1.10%), XAV HEALTH CARE JUN26 (0.00%), XAK TECHNOLOGY JUN26 (0.00%).
Asset categories and pricing
as of 2026-06-3097.76% equity, 2.24% short-term investment as filed; 100.0% carried at a quoted market price (fair-value level 1). Categories and levels are the filer's; what a low level-1 share does and does not mean is in the measure's page.
Derivative exposure and counterparties
as of 2026-06-30A position count cannot describe a fund that uses derivatives, because a swap is filed at its unrealised gain, not its exposure. These are the notionals the fund itself reported, against net assets of $3.02B. Notional of an interest-rate or currency swap is not equity exposure.
Full detail for every fund that files derivatives: leverage.json (CC BY 4.0).
Neighbours by effective holdings, equity funds
10Every measured equity fund lined up by how many holdings it behaves like; these sit either side of IHI (11.9). Same filings, same arithmetic. Position in this list says nothing about which fund is better.
| Fund | Reports | Behaves like | Top ten | As of |
|---|---|---|---|---|
| RAAX VanEck Real Assets ETF | 126 | 11.7 | 56.45% | 2026-06-30 |
| PPH VanEck Pharmaceutical ETF | 25 | 11.7 | 73.08% | 2026-06-30 |
| EWP iShares MSCI Spain ETF | 25 | 11.8 | 73.78% | 2026-05-31 |
| FENY Fidelity MSCI Energy Index ETF | 103 | 11.9 | 65.1% | 2026-07-31 |
| QAI NYLIM Hedge Multi-Strategy Tracker ETF | 60 | 11.9 | 69.96% | 2026-07-31 |
| BUFD FT Vest Laddered Deep Buffer ETF | 13 | 12 | 83.3% | 2026-05-31 |
| BUFZ FT Vest Laddered Moderate Buffer ETF | 13 | 12 | 83.31% | 2026-05-31 |
| SOXL Direxion Daily Semiconductor Bull 3X Shares | 38 | 12.1 * | 63.99% | 2026-07-31 |
| EWH iShares MSCI Hong Kong ETF | 31 | 12.1 | 66.65% | 2026-05-31 |
| EPHE iShares MSCI Philippines ETF | 38 | 12.1 | 61.95% | 2026-05-31 |
Essays that examine IHI
0Mentions are detected across the full text of every article, so an appearance may be a passing comparison rather than the subject. Nothing here is a recommendation to buy or sell — see the disclaimer.